CD6 and Its Interacting Partners: Newcomers to the Block of Cancer Immunotherapies
Cancer management still requires more potent and safer treatments, of which immunomodulatory receptors on the lymphocyte surface have started to show promise in new cancer immunotherapies (e.g., CTLA-4 and PD-1). CD6 is a signal-transducing transmembrane receptor, mainly expressed by all T cells and...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-12-01
|
| Series: | International Journal of Molecular Sciences |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1422-0067/24/24/17510 |
| _version_ | 1797380659354796032 |
|---|---|
| author | Lucía Aragón-Serrano Laura Carrillo-Serradell Violeta Planells-Romeo Marcos Isamat María Velasco-de Andrés Francisco Lozano |
| author_facet | Lucía Aragón-Serrano Laura Carrillo-Serradell Violeta Planells-Romeo Marcos Isamat María Velasco-de Andrés Francisco Lozano |
| author_sort | Lucía Aragón-Serrano |
| collection | DOAJ |
| description | Cancer management still requires more potent and safer treatments, of which immunomodulatory receptors on the lymphocyte surface have started to show promise in new cancer immunotherapies (e.g., CTLA-4 and PD-1). CD6 is a signal-transducing transmembrane receptor, mainly expressed by all T cells and some B and NK cell subsets, whose endogenous ligands (CD166/ALCAM, CD318/CDCP-1, Galectins 1 and 3) are overexpressed by malignant cells of different lineages. This places CD6 as a potential target for novel therapies against haematological and non-haematological malignancies. Recent experimental evidence for the role of CD6 in cancer immunotherapies is summarised in this review, dealing with diverse and innovative strategies from the classical use of monoclonal antibodies to soluble recombinant decoys or the adoptive transfer of immune cells engineered with chimeric antigen receptors. |
| first_indexed | 2024-03-08T20:40:26Z |
| format | Article |
| id | doaj.art-03b780b318ee4f29a265cec86340d4ab |
| institution | Directory Open Access Journal |
| issn | 1661-6596 1422-0067 |
| language | English |
| last_indexed | 2024-03-08T20:40:26Z |
| publishDate | 2023-12-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | International Journal of Molecular Sciences |
| spelling | doaj.art-03b780b318ee4f29a265cec86340d4ab2023-12-22T14:14:53ZengMDPI AGInternational Journal of Molecular Sciences1661-65961422-00672023-12-0124241751010.3390/ijms242417510CD6 and Its Interacting Partners: Newcomers to the Block of Cancer ImmunotherapiesLucía Aragón-Serrano0Laura Carrillo-Serradell1Violeta Planells-Romeo2Marcos Isamat3María Velasco-de Andrés4Francisco Lozano5Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Rosselló 149-153, 08036 Barcelona, SpainInstitut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Rosselló 149-153, 08036 Barcelona, SpainInstitut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Rosselló 149-153, 08036 Barcelona, SpainSepsia Therapeutics S.L., 08908 L’Hospitalet de Llobregat, SpainInstitut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Rosselló 149-153, 08036 Barcelona, SpainInstitut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Rosselló 149-153, 08036 Barcelona, SpainCancer management still requires more potent and safer treatments, of which immunomodulatory receptors on the lymphocyte surface have started to show promise in new cancer immunotherapies (e.g., CTLA-4 and PD-1). CD6 is a signal-transducing transmembrane receptor, mainly expressed by all T cells and some B and NK cell subsets, whose endogenous ligands (CD166/ALCAM, CD318/CDCP-1, Galectins 1 and 3) are overexpressed by malignant cells of different lineages. This places CD6 as a potential target for novel therapies against haematological and non-haematological malignancies. Recent experimental evidence for the role of CD6 in cancer immunotherapies is summarised in this review, dealing with diverse and innovative strategies from the classical use of monoclonal antibodies to soluble recombinant decoys or the adoptive transfer of immune cells engineered with chimeric antigen receptors.https://www.mdpi.com/1422-0067/24/24/17510cancerimmunotherapyCD6scavenger receptorsCD166/ALCAMCD318/CDCP1 |
| spellingShingle | Lucía Aragón-Serrano Laura Carrillo-Serradell Violeta Planells-Romeo Marcos Isamat María Velasco-de Andrés Francisco Lozano CD6 and Its Interacting Partners: Newcomers to the Block of Cancer Immunotherapies International Journal of Molecular Sciences cancer immunotherapy CD6 scavenger receptors CD166/ALCAM CD318/CDCP1 |
| title | CD6 and Its Interacting Partners: Newcomers to the Block of Cancer Immunotherapies |
| title_full | CD6 and Its Interacting Partners: Newcomers to the Block of Cancer Immunotherapies |
| title_fullStr | CD6 and Its Interacting Partners: Newcomers to the Block of Cancer Immunotherapies |
| title_full_unstemmed | CD6 and Its Interacting Partners: Newcomers to the Block of Cancer Immunotherapies |
| title_short | CD6 and Its Interacting Partners: Newcomers to the Block of Cancer Immunotherapies |
| title_sort | cd6 and its interacting partners newcomers to the block of cancer immunotherapies |
| topic | cancer immunotherapy CD6 scavenger receptors CD166/ALCAM CD318/CDCP1 |
| url | https://www.mdpi.com/1422-0067/24/24/17510 |
| work_keys_str_mv | AT luciaaragonserrano cd6anditsinteractingpartnersnewcomerstotheblockofcancerimmunotherapies AT lauracarrilloserradell cd6anditsinteractingpartnersnewcomerstotheblockofcancerimmunotherapies AT violetaplanellsromeo cd6anditsinteractingpartnersnewcomerstotheblockofcancerimmunotherapies AT marcosisamat cd6anditsinteractingpartnersnewcomerstotheblockofcancerimmunotherapies AT mariavelascodeandres cd6anditsinteractingpartnersnewcomerstotheblockofcancerimmunotherapies AT franciscolozano cd6anditsinteractingpartnersnewcomerstotheblockofcancerimmunotherapies |